This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-09. Anything still debated is marked as such rather than presented as settled.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
=== Alexander Norton === Viscount Alexander Norton (Andrew Havill) is Henry Muck’s uncle and a powerful newspaper proprietor who owns several British tabloids. A wealthy aristocrat with a large country estate, he is a former Oxford classmate of Charles Hanani and a close ally of Otto Mostyn. In series 3, Norton works with Otto and Conservative MP Aurore Adekunle to exploit the collapse of Lumi and the failed Barclays acquisition of Pierpoint for political advantage. As Yasmin faces mounting negative press following her father’s embezzlement scandal and death, Norton offers to suppress damaging coverage and urges her to marry Henry, assuring her of his family’s protection and financial security. He also tells Yasmin he had long known of Charles’s predatory behavior and that she bears no responsibility. In series 4, Norton remains involved in Henry’s life after his brief parliamentary career ends. Aware that Henry’s father died by suicide on his 40th birthday, Norton unsuccessfully tries to lift him from a depressive spiral during the same milestone. He meets with Labour MP Jennifer Bevan, Henry’s successor, who confronts him about his alarmist headlines about the economy, which she fears could contribute to a recession. Norton tells her that her superior, far-left business secretary Lisa Dearn, is "anti-business". After Henry becomes CEO of fintech company Tender, Yasmin enlists Norton to run headlines smearing financial journalist James Dycker (who is investigating Tender) as colluding with short sellers, which helps contribute to Dycker's firing.
He said that this lake often changes its shape and place, which he expressed in these terms: the lake moves. Often, he added, on going to a place which the evening before was quite solid, you suddenly break through, and disappear in the abyss. But what is more frightful is the overflow of the waters: sometimes the lake rises like a mountain, and falls again into the plain like a deluge; entire caravans, men and beasts are engulphed. There are, however, precursory signs, of which mounted men only can take advantage, by flying at the utmost speed of the animals; occasionally some of them have thus escaped, and it is from them these terrible details are procured.
Counter-Strike is a team-based multiplayer first-person shooter video game in which players play as Terrorists (T) or Counter-Terrorists (CT). Each game begins with both teams spawning simultaneously as one of eight possible default character models (four each for Counter-Terrorist and Terrorist). Each player begins with $800, two magazines of ammo, a knife, and a handgun: a Heckler & Koch USP for the Counter-Terrorists or a Glock 18c for the Terrorists. Players are usually allowed a few seconds before the round starts to purchase equipment but not move. They may purchase equipment whenever they are in a buy zone for their team. When players are killed, they become spectators for the rest of the round. They may typically watch the rest of the round from a variety of chosen observer modes. At the end of each round, players receive money for the next round: $3,500 for winning a round, $1,500 for losing one, and $300 for killing an enemy, up to a maximum total of $16,000. Players can be fined, or lose money, by killing a teammate or a hostage. Depending on the map, there are 3 possible objectives to win (in addition to eliminating all enemy team members):
Masculinizing hormone therapy – for transgender men or transmasculine people; consists of androgens and occasionally antiestrogens. Feminizing hormone therapy – for transgender women or transfeminine people; consists of estrogens with or without antiandrogens. Eligibility for GAHT may require an assessment for gender dysphoria or persistent gender incongruence; many medical institutions now use an informed consent model, which ensures patients are informed of the procedure process, including possible benefits and risks, while removing many of the historical barriers needed to start hormone therapy. Treatment guidelines for therapy have been developed by several medical associations. However, many transgender people of all ages safely obtain and administer hormone therapy to themselves (DIY transgender hormone therapy) without recourse to institutional 'gatekeepers'. This helps them to overcome legal barriers to care, and to obtain higher, more effective dosages and a wide range of medications. Non-binary people may also engage in hormone therapy in order to achieve a desired balance of sex hormones or to help align their bodies with their gender identities. Many transgender people obtain hormone replacement therapy from a licensed health care provider, while others obtain and self-administer hormones.
=== Post-Commonwealth era === Regions were first formed on September 24, 1972 when the provinces of the Philippines were organized into different 11 regions by Presidential Decree No. 1 as part of the Integrated Reorganization Plan of President Ferdinand Marcos. Negros Occidental was assigned to Western Visayas (Region VI) and Negros Oriental was assigned to Central Visayas (Region VII).
Sources: en.wikipedia.org
Halliwell B; Gutteridge JM (1984). "Oxygen toxicity, oxygen radicals, transition metals and disease". Biochemical Journal. 219 (1): 1–14. doi:10.1042/bj2190001. PMC 1153442. PMID 6326753. Murphy MP, Bayir H, Belousov V, Chang CJ, Davies KJ, Davies MJ, Dick TP, Finkel T, Forman HJ, Gems D, Janssen-Heininger Y, Kagan VE, Kalyanaraman B, Larsson NG, Mile GL, Nyström T, Poulsen HE, Radi R, Remmen HV, Schumacker PT, Thornalley PJ, Toyokuni S, Winterbourn CC, Yin H, Halliwell B. (2022) Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nature Metabolism 4, 651–662. Research articles
Selective cleavage of Arg18-Gly19 and Arg46-Thr47 bonds in coagulogen to form coagulin and fragments This enzyme is present in the hemocyte granules of horseshoe crabs Limulus and Tachypleus. In the immunity-related clotting pathways of these organisms, it is the final enzyme responsible for the activation of coagulin.
==== Macau ==== 7-Eleven entered the Macau market in 2005 under the ownership of Dairy Farm, a Hong Kong-based conglomerate operating 7-Eleven stores in Hong Kong. With a land area of about 33.3 square kilometers (12.9 sq mi) in 2024, Macau has 45 stores.
==== Libya ==== The mummified remains of an infant were discovered during an expedition by archaeologist Fabrizio Mori to Libya during the winter of 1958–1959 in the natural cave structure of Uan Muhuggiag. After curious deposits and cave paintings were discovered on the surfaces of the cave, expedition leaders decided to excavate. Uncovered alongside fragmented animal bone tools was the mummified body of an infant, wrapped in animal skin and wearing a necklace made of ostrich egg shell beads. Professor Tongiorgi of the University of Pisa radiocarbon-dated the infant to between 5,000 and 8,000 years old. A long incision located on the right abdominal wall, and the absence of internal organs, indicated that the body had been eviscerated post-mortem, possibly in an effort to preserve the remains. A bundle of herbs found within the body cavity also supported this conclusion. Further research revealed that the child had been around 30 months old at the time of death, though sex could not be determined due to poor preservation of the sex organs.
The ability of a drug or other substance to be absorbed and used by the body. Orally bioavailable means that a drug or other substance that is taken by mouth can be absorbed and used by the body. (NCI) Bioinformatics
Sources: en.wikipedia.org
(p) .signature (UNIX shell/Internet standard file name) (a/i) Special Interest Group (a/i) Strasbourg Illkirch-Graffenstaden Basket (French basketball club) SIGCAT – (a) Special Interest Group for CD-ROM Applications and Technology SIGINT – (p) Signals Intelligence SIGMET – (p) Significant Meteorological Information SIIT (i) Saskatchewan Indian Institute of Technologies (Canadian university) Sirindhorn International Institute of Technology (Thai university) Stateless IP/ICMP Translation algorithm SIMAC – (a) Semantic Interaction with Music Audio Contents SIMLAS – (p) Soldier Integrated Multipurpose Laser System SIMM – (a) Single In-line Memory Module SIMNET – (p) SIMulator NETwork, later SIMulation NETwork SIMNET-D - (p) SIMNET-Developmental SIMP – (a) Strongly Interacting Massive Particle SIMPLE (a) Satellite Interactive Multimedia Platform for Low-cost Earth stations (p) Savings Incentive Match Plan for Employees (as used in SIMPLE IRA) (a) Standard Interface for Multiple Platform Link Evaluation (NATO STANAG 5602) sin – (s) Sinhala language (ISO 639-2 code) SIN – (a) Social insurance number (Canada) SINCGARS – (p) SINgle Channel Ground and Airborne Radio System SIP (i) Session Initiation Protocol State Implementation Plan System Improvement Program Systematic investment plan SIPP – (a) Self-Invested Personal Pension Siri – (a) Speech Interpretation and Recognition Interface (Apple iOS software) SIRI – (a) Service Interface for Real Time Information SIRS — (a) Systemic inflammatory response syndrome SiS – (i) Silicon Integrated Systems SIS – (i) UK Secret Intelligence Service (also known as MI6) SISO (a) Simulation Interoperability Standards Organization Society of Independent Show Organizers SIW – (i) Simulation Interoperability Workshop SIYSS – (i) Stockholm International Youth Science Seminar
Colin Pitchfork was arrested in 1987 and it was found that his DNA profile matched the semen samples from the murder. Because of this case, DNA databases were developed. There is the national (FBI) and international databases as well as the European countries (ENFSI: European Network of Forensic Science Institutes). These searchable databases are used to match crime scene DNA profiles to those already in a database.
=== Source 2, virtual reality and Half-Life: Alyx (2015–present) === Valve announced the Source 2 engine in March 2015, and ported Dota 2 to Source 2 in September. That year, Valve collaborated with the electronics company HTC to develop the HTC Vive, a VR headset released in 2016. Valve experimented with VR games, and in 2016 released The Lab, a collection of VR minigames. Valve recognized that many players wanted a more ambitious VR AAA game, and began exploring the development of a major VR game. They developed several prototypes, with three further VR projects under development by 2017. Finding that the portal systems of its puzzle series Portal were disorienting in VR, it settled on Half-Life. Walker said that Half-Life 3 had been a "terrifyingly daunting prospect", and the team saw VR as a way to return to the series. Full development of a VR Half-Life game started around late 2016, with the largest team in Valve's history. Valve acquired the 3D audio software developer Impulsonic in January 2017. In April 2018, Valve acquired the independent developer Campo Santo, known for the 2016 adventure game Firewatch. Campo Santo planned to develop its own games under Valve, though it initially helped develop Half-Life: Alyx. In November 2018, Valve released Artifact, a digital collectible card game based on Dota 2, with design by Richard Garfield, the creator of Magic: The Gathering. Artifact had unusual pay-for mechanics to acquire new cards, and did not draw a large playerbase, losing 95% of players months after release.
Whereas the biological half-life of estradiol given by intravenous injection is about 0.5 to 2 hours, the biological half-life of oral estradiol has a range of 13 to 20 hours due to the large and long-lasting pool of estrogen conjugates that is formed during first-pass metabolism and that serves to continuously replenish circulating estradiol levels.
In cladistics, a homoplasy is a trait shared by two or more taxa for any reason other than that they share a common ancestry. Taxa which do share ancestry are part of the same clade; cladistics seeks to arrange them according to their degree of relatedness to describe their phylogeny. Homoplastic traits caused by convergence are therefore, from the point of view of cladistics, confounding factors which could lead to an incorrect analysis.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.